Table 1.
BRAF mutations and clinical characteristics
| Clinical Features | BRAF Status | P value | |
| Mutation N = 30 (44.1%) | Wild Type N = 38 (55.9%) | ||
| Gender | |||
| Female | 11 | 15 | 0.81 |
| Male | 19 | 23 | |
| Age1 | |||
| Mean | 63.3 | 57.3 | 0.12 |
| Median (range) | 56.5 (29–91) | 65.0 (42–97) | |
| Stage at Diagnosis | |||
| I | 5 | 3 | 0.92 |
| II | 13 | 19 | |
| III | 7 | 10 | |
| IV | 4 | 2 | |
| Unknown | 1 | 4 | |
| Thickness (Number available) | (N = 18) | (N = 22) | |
| Mean | 2.98 | 4.83 | 0.29 |
| Median (range) | 1.75 (0.2, 20) | 2.80 (0.4, 35) | |
| Primary Site | |||
| Head/Neck | 1 | 6 | |
| Trunk | 10 | 11 | |
| Extremities | 10 | 14 | |
| Ocular | 1 | 0 | |
| Mucosal | 1 | 0 | |
| Unknown | 7 | 7 | |
| Response2 | |||
| CR | 2 | 3 | |
| PR | 0 | 2 | |
| NR | 16 | 10 | |
| Response Rate | 11% | 33% | 0.12 |
1 Age at time of biopsy used to assess BRAF sequence.
2 Response data is based on the 33 patients who received systemic therapy.